Basic demographics
| . | Response . | ||||
|---|---|---|---|---|---|
| Total, n = 99 (%) . | Unchanged (n = 40) . | Increased (n = 29) . | Decrease (n = 30) . | Discrepancy, n = 59 (%) . | |
| Disease | |||||
| AML | 17 (17.2) | 10 | 4 | 3 | 7 (11.8) |
| ALL | 5 (5) | 2 | 1 | 2 | 3 (5.1) |
| CML | 2 (2) | 0 | 2 | 0 | 2 (3.4) |
| CLL | 15 (15.2) | 6 | 5 | 4 | 9 (15.3) |
| NHL | 25 (25.3) | 11 | 7 | 7 | 14 (23.7) |
| HL | 5 (5) | 1 | 2 | 2 | 4 (6.8) |
| MM | 27 (27.3) | 10 | 7 | 10 | 17 (28.8) |
| Amyloidosis | 1 (1) | 0 | 1 | 0 | 1 (1.7) |
| Myelofibrosis | 1 (1) | 0 | 0 | 1 | 1 (1.7) |
| WM | 1 (1) | 0 | 0 | 1 | 1 (1.7) |
| Study type | |||||
| Phase 1 | 10 (10) | 4 | 2 | 4 | 6 (10.2) |
| Phase 2 | 74 (75) | 23 | 27 | 24 | 51 (86.4) |
| Phase 3 | 15 (15) | 13 | 0 | 2 | 2 (3.4) |
| Centers involved | |||||
| Single | 31 (31) | 7 | 12 | 12 | 24 (41) |
| Multi | 68 (69) | 33 | 17 | 18 | 35 (59) |
| National/international study groups | 11 (11) | 4 | 3 | 4 | 7 (11.8) |
| Pharma-sponsored | 52 (52) | 26 | 11 | 15 | 26 (44) |
| Meeting | |||||
| ASH | 85 (86) | 34 | 26 | 25 | 51 (86.4) |
| ASCO | 13 (13) | 6 | 3 | 4 | 7 (11.9) |
| EHA | 1 (1) | 0 | 0 | 1 | 1 (1.7) |
| Journal | |||||
| Blood | 51 (52) | 20 | 13 | 18 | 31 (52.5) |
| NEJM | 7 (7) | 3 | 1 | 3 | 4 (6.8) |
| Lancet | 9 (9) | 6 | 2 | 1 | 3 (5.1) |
| JCO | 25 (25) | 9 | 10 | 6 | 16 (27.1) |
| Haematologica | 5 (5) | 1 | 2 | 2 | 4 (6.8) |
| Leukemia | 2 (2) | 1 | 1 | 0 | 1 (1.7) |
| . | Response . | ||||
|---|---|---|---|---|---|
| Total, n = 99 (%) . | Unchanged (n = 40) . | Increased (n = 29) . | Decrease (n = 30) . | Discrepancy, n = 59 (%) . | |
| Disease | |||||
| AML | 17 (17.2) | 10 | 4 | 3 | 7 (11.8) |
| ALL | 5 (5) | 2 | 1 | 2 | 3 (5.1) |
| CML | 2 (2) | 0 | 2 | 0 | 2 (3.4) |
| CLL | 15 (15.2) | 6 | 5 | 4 | 9 (15.3) |
| NHL | 25 (25.3) | 11 | 7 | 7 | 14 (23.7) |
| HL | 5 (5) | 1 | 2 | 2 | 4 (6.8) |
| MM | 27 (27.3) | 10 | 7 | 10 | 17 (28.8) |
| Amyloidosis | 1 (1) | 0 | 1 | 0 | 1 (1.7) |
| Myelofibrosis | 1 (1) | 0 | 0 | 1 | 1 (1.7) |
| WM | 1 (1) | 0 | 0 | 1 | 1 (1.7) |
| Study type | |||||
| Phase 1 | 10 (10) | 4 | 2 | 4 | 6 (10.2) |
| Phase 2 | 74 (75) | 23 | 27 | 24 | 51 (86.4) |
| Phase 3 | 15 (15) | 13 | 0 | 2 | 2 (3.4) |
| Centers involved | |||||
| Single | 31 (31) | 7 | 12 | 12 | 24 (41) |
| Multi | 68 (69) | 33 | 17 | 18 | 35 (59) |
| National/international study groups | 11 (11) | 4 | 3 | 4 | 7 (11.8) |
| Pharma-sponsored | 52 (52) | 26 | 11 | 15 | 26 (44) |
| Meeting | |||||
| ASH | 85 (86) | 34 | 26 | 25 | 51 (86.4) |
| ASCO | 13 (13) | 6 | 3 | 4 | 7 (11.9) |
| EHA | 1 (1) | 0 | 0 | 1 | 1 (1.7) |
| Journal | |||||
| Blood | 51 (52) | 20 | 13 | 18 | 31 (52.5) |
| NEJM | 7 (7) | 3 | 1 | 3 | 4 (6.8) |
| Lancet | 9 (9) | 6 | 2 | 1 | 3 (5.1) |
| JCO | 25 (25) | 9 | 10 | 6 | 16 (27.1) |
| Haematologica | 5 (5) | 1 | 2 | 2 | 4 (6.8) |
| Leukemia | 2 (2) | 1 | 1 | 0 | 1 (1.7) |
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; EHA, European Hematology Association; HL, Hodgkin lymphoma; JCO, Journal of Clinical Oncology; MM, multiple myeloma; NEJM, New England Journal of Medicine; NHL, non-Hodgkin lymphoma; WM, Waldenstrom macroglobulinemia.